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Angiostrongylus  vasorum  is an  increasingly  reported  parasite  in Europe  that  develops  in
dogs after ingestion  of infective  third  stage  larvae  (L3)  that reside  in  gastropod  molluscs
which  are  needed  to complete  the  parasite’s  life-cycle.  Infection  can  produce  a diversity
of clinical  signs,  determined  by involvement  of  the  respiratory,  neurological,  and/or  coag-
ulation system,  with  a likely  fatal  outcome  in  the  absence  of treatment.  Few  drugs  have
been shown  to reliably  prevent  infection,  and  data  on  treatment  of  infections  is  limited.
A controlled,  randomized,  partially  blinded  laboratory  study  was  therefore  executed  to
evaluate the  efﬁcacy  and  safety  of  a combination  tablet  of  spinosad/milbemycin  oxime
in dogs  inoculated  with  approximately  250  A.  vasorum  L3.  Sixteen  healthy  nematode  free
adult dogs  were  randomly  allocated  to two  study  groups  of  8 dogs  each.  Thirty  days  post
inoculation  (dpi)  all dogs  in the fed  state  were  treated:  dogs  in  group  B were  treated  with
spinosad  and  milbemycin  oxime  at the dose  rates  of  45–60  mg/kg  and  0.75–1.0  mg/kg  body-
weight,  respectively,  approximately  the  lower  half portion  of the expected  full  unit dose
range;  dogs  in  group  A  were  treated  with  placebo  tablets.  All  dogs  were  euthanized  and
necropsied  56–58  dpi.  The  heart and  lungs  were  examined  to  determine  the  presence  of  A.
vasorum. All placebo  group  dogs  were  infected  at necropsy  with  counts  ranging  from  22
to 98  adult  worms  and  a geometric  mean  worm  count  of  55.2.  In contrast,  the  geometric
mean  worm  count  in  the  spinosad/milbemycin  oxime  group  was  0.7  with  worm  numbers
ranging  from  0  to 8.  The  results  of this  study  demonstrate  that  a single  treatment  with  the
tablet combination  of  spinosad  and  milbemycin  oxime  administered  30  dpi  provided  98.8%
preventive  efﬁcacy  against  development  of  adult  A.  vasorum  infections.  Monthly  treatments
with  spinosad  and  milbemycin  oxime  have  the  potential  to prevent  the  establishment  of
infections  with  A.  vasorum
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1. Introduction
Adult worms of Angiostrongylus vasorum (Nematoda,
Open access under CC BY-NC-SA license.Metastrongylidae, Baillet 1866) live in the pulmonary
arteries and the right atrium and ventricle of the heart
of  the ﬁnal hosts, which include domestic dogs, foxes
(Guilhon, 1963; Sreter et al., 2003), wolves (Segovia et al.,
-NC-SA license.
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2001) and badgers (Torres et al., 2001). In dogs patency
(excretion of ﬁrst stage larvae) is usually between 38 and 57
days  after infection but can range from 28 to 108 days after
infection (Bolt et al., 1994). Clinical signs are attributed
to inﬂammation caused by the presence of the parasite’s
eggs and larval stages in the lungs and can range from a
cough,  dyspnoea and further respiratory signs, through a
bleeding  diathesis that can manifest with gastrointestinal
or neurological signs (Chapman et al., 2004; Schnyder et al.,
2010).  If not treated, infections in dogs may  be progressive
and potentially carry a fatal outcome (Staebler et al., 2005;
Traversa et al., 2008).
Often  called the French Heartworm from its ﬁrst
recorded incidence in France in the 1800s (Serres, 1854),
the  geographic range of A. vasorum is now known to
have expanded throughout Europe. Initial observations in
Ireland  were reported in 1968 (Roche and Kelliher, 1968)
and  parasite’s presence in the UK in 1975 (Jacobs and Prole,
1975),  where it now appears to have spread from the area
of  original identiﬁcation in southern England throughout
the country (reviewed by Yamakawa et al., 2009). The
widespread presence of the parasite is suggested by preva-
lence  surveys performed in foxes and dogs in Italy (Poli
et  al., 1991; Guardone et al., 2013; Di Cesare et al., 2011); an
apparent  endemic focus in Denmark (Koch and Bolt, 1990);
and  from sporadic cases reported across Europe, includ-
ing  in Sweden (Ablad et al., 2003), Greece (Papazahariadou
et al., 2007), Hungary (Sreter et al., 2003), Switzerland
(Staebler et al., 2005) and Germany (Barutzki and Schaper,
2009; Seybold, 2011). Higher incidence rates were reported
by  other authors in a 4 year long epidemiological overview
including samples from dogs in Germany and Denmark
(Taubert et al., 2008).
The  increasing reports of this parasite and its distribu-
tion all over Europe and also in Canada, drive the need for
effective treatment and even more importantly, preven-
ting  the establishment of infection. Treatments shown to
be  effective against infections with A. vasorum include the
orally  administered compounds fenbendazole and milbe-
mycin  oxime, and the topically applied combination of
imidacloprid/moxidectin. Fenbendazole administered per
os  at 25–50 mg/kg bodyweight (BW) for 20 days has been
reported to be effective (Willesen et al., 2007), while a
single  application of imidacloprid 10%/moxidectin 2.5%
spot-on (0.1 ml/kg bodyweight) was 85.2% effective against
adult  A. vasorum (Willesen et al., 2007). Administration of
that  topical product was reported to be effective against
experimental A. vasorum infections when administered as
a  single treatment once at 4 days, and to a second group at
32  days post inoculation (Schnyder et al., 2009).
Spinosad is a novel tetracyclic macrolide insecticide
recently approved as an orally administered tablet for the
treatment and prevention of ﬂea infestations in dogs and
cats.  A single oral treatment has been shown effective
against ﬂeas on dogs, and consecutive monthly treat-
ments have been shown to provide >99% control of ﬂeas
in  client-owned dogs (Wolken et al., 2012; Dryden et al.,
2013).  Milbemycin oxime (MO) is a macrocyclic lactone
anthelmintic which has been shown to be effective against
larval  stages of the heartworm Diroﬁlaria immitis, as well
as  against a range of gastrointestinal parasites. The broadlogy 199 (2014) 272– 277 273
spectrum efﬁcacy and safety of a combination tablet of
spinosad with MO has been demonstrated in studies on
ﬂea  infestations and on infections with gastrointestinal
nematodes, including Ancylostoma caninum, Toxocara canis,
Toxascaris  leonina, Trichuris vulpis and the heartworm D.
immitis  (Snyder et al., 2011; Snyder and Wiseman, 2012;
Schnitzler et al., 2012). Against A. vasorum, one report indi-
cated  that an oral dose of MO  (0.5 mg/kg BW)  administered
as a single product, cleared larval excretion in 14 of 16
(87.5%) infected dogs when given weekly over four weeks
(Conboy, 2004).
The  purpose of this study was  to investigate the pro-
phylactic effectiveness of a single treatment of an oral
combination tablet containing spinosad and MO  against
immature stages of A. vasorum in dogs. As this was a study
undertaken to support a registration claim, treatment was
administered using dose rates of 45–60 mg/kg BW spinosad
and  0.75–1.00 mg/kg BW MO,  approximately the lower
half  of the expected full unit dose range (45–70 mg/kg BW
spinosad and 0.75–1.18 mg/kg BW MO).
2.  Materials and methods
The  study was  conducted as a controlled, random-
ized, partially blinded study adhering to the standards of
Good  Clinical Practice and VICH (http://www.vichsec.org/,
International Cooperation on Harmonisation of Techni-
cal  Requirements for Registration of Veterinary Medicinal
Products) guidelines (GL7 and GL19). The study was
conducted at the Institute of Parasitology, University of
Veterinary Medicine, Hanover in Germany. The protocol
was reviewed and approved by the laboratory’s Institu-
tional Animal Care and Ethics Committee.
2.1. Dogs
Sixteen healthy beagle dogs, 8 male and 8 female,
approximately 10 months of age, were included in the
study. Faecal samples were collected from each of the study
dogs  in the week prior to inoculation with A. vasorum third
stage  larvae (L3) to verify that none were carrying any
existing gastrointestinal nematode infections. Qualitative
faecal examinations were conducted using the Baermann
technique (standard amount of faeces, 10 g/dog, examina-
tion  for larvae after 24 h of incubation, Baermann, 1917)
in  combination with a sedimentation-ﬂotation technique
(Eckert, 1972). A negative nematode status was required
for  inclusion and enrolment into the study. All dogs were
individually housed in kennels with concrete ﬂoors and
wooden stands and were fed a commercial dry dog food
ration with ad libitum access to tap water (see Table 1
for  schedule of events). All personnel responsible for clini-
cal  observations or for performing nematode counts were
blinded  to the treatments.
2.2.  Experimental inoculationFirst  stage larvae of A. vasorum were harvested from a
fox  infected with a ﬁeld isolate, originally obtained from
dogs  in Denmark and passaged twice by the Faculty of
Health and Medical Science, University of Copenhagen,
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Table  1
Study schedule of events.
Study day Event
Day-37 to Day-30 Dog acclimatization pre-treatment faecal samples collected
Day-30 Physical examinations Infection of all dogs with 250 third-stage larvae of Angiostrongylus vasorum
Day  0 Physical examination pre- and post-treatment dosing
Days 4, 7, 12, 14, 19, 22 Thoracic auscultation for respiratory assessments
Days 26–28 (56–58 days Necropsy
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enmark. The larvae were shipped to the trial facility for
nfection of snails (Achatina fulica). Third stage larvae were
arvested from the snails by peptic digestion.
For infection with A. vasorum, general anaesthesia was
erformed on Day-30 with intravenous acepromazine
Vetranquil®, 0.4 ml/kg BW)  and propofol (Narcofol®,
.6  ml/kg BW). Each anaesthetized dog was inoculated by
tomach  tube with approximately 250 L3, and then was
losely  monitored to verify that regurgitation of the inoc-
lation  dose did not occur.
.3.  Randomization and treatment
Using a standard statistical program (SAS® version 9.2)
ach  dog was randomly assigned, without blocking, to one
f  two treatment groups. Group B dogs were treated orally
ith  a tablet containing spinosad and MO  at respective
ose rates of 45–60 mg/kg BW and 0.75–1.0 mg/kg BW,
eceiving therefore approximately the lower half portion
f  the dose range (45–70 mg/kg BW and 0.75–1.18 mg/kg
W). Group A dogs were treated with a placebo tablet con-
aining  no active ingredient, but identical in appearance to
hose  containing active drug.
Treatments were administered 30 days post inoculation
dpi) on Day 0 to dogs according to their randomization to
 treatment group. To optimize absorption of spinosad and
O,  tablets are recommended to be given with food. There-
ore,  on the evening prior to dosing, food was removed from
he  animal housing areas and on the following morning
ach dog was allowed to consume approximately 25% of
he  manufacturer’s recommended daily amount of a palat-
ble  dry dog food, based on body weight. Study tablets were
hen  administered, after which all dogs were offered the
emainder of their standard daily maintenance diet.
.4.  Clinical examinations
Clinical  examinations were performed before inocula-
ion and then during the pre-treatment phase. On the day of
reatment  (Day 0), dogs were observed pre-dosing, at 1 and
 h (±15 min.) post dosing, and again at 4 and 8 h (±30 min.)
ost  dosing by the animal care taker. On subsequent
ays, two veterinarians trained in a standardized facility
rocedure recorded their clinical observations, includ-
ng  respiratory assessments. From the day after dosing
31  dpi), twice weekly auscultatory respiratory assess-
ents were performed with the quality (normal/deepened
ormal sound/stertor/stridor/rhonchus/wheeze/crackle),
nd  intensity of inspiratory and expiratory sounds gradedon  a scale from 0 (no abnormal sound) to 3 (severe sound).
In  addition, faecal sampling was performed from 40 dpi
until  a dog was  conﬁrmed to be shedding larvae using the
methods described above (Baermann, 1917).
2.5. Necropsies
Dogs were euthanized and necropsied on Days 26–28
post-treatment (56–58 dpi). Post-necropsy examinations
were carried out following Schnyder et al. (2009). For each
dog,  the heart and lungs were examined in detail to deter-
mine  the presence or absence of adult A. vasorum. All
worms were counted and identiﬁed to gender and stage of
development, whenever possible. If worm fragments were
present,  they were only included in the count if the head
was  present.
2.6.  Statistics
Efﬁcacy calculations were based on the total number of
adult  worms recovered from each dog at necropsy in the
treated  and control groups to determine whether or not
treatment had prevented development of infections with
adult  A. vasorum. To show adequate infection, a minimum
of  ﬁve A. vasorum must have been present in at least 6
control dogs. For each treatment group, the total number
of  adult A. vasorum along with the group geometric mean
(GM)  was calculated.
The  mean worm counts were determined and compared
post-treatment between treated (spinosad/MO combina-
tion) and control (placebo) groups. Efﬁcacy was calculated
based on GM using the formula:
%Efﬁciency =
{
meancontrol − meantreated
meancontrol
}
× 100
To demonstrate prevention, both of the following crite-
ria  must have been satisﬁed:
1.  Efﬁcacy ≥90% against A. vasorum with the combination
tablet, based on GM.
2. A statistically signiﬁcant difference (p < 0.05, two-sided)
between the control group and the combination treated
group based on analysis of transformed counts of adult
A. vasorum.A logarithmic transformation (ln[count + 1]) was
applied to the post-treatment counts for each dog to
address skewness of the data, as well as zero counts. Back
transformed geometric means were calculated by ex − 1,
 Parasitology 199 (2014) 272– 277 275
Fig. 1. Lung lobes and heart from a dog inoculated with 250 third stage
larvae of Angiostrongylus vasorum and treated with the spinosad/MO com-
bination 30 days later, having 0 worm counts at necropsy performed 26
days after treatment.
Fig. 2. Lung lobes and heart from a dog of the placebo-treated group inoc-C. Böhm et al. / Veterinary
where x¯ equals log transformed treatment mean. Trans-
formed GM worm counts were analyzed with a general
linear mixed model with ﬁxed effect treatment. A contrast
between spinosad/MO and the placebo groups was con-
ducted  to conﬁrm effectiveness. A covariance structure
allowing for heterogeneous error variance between treat-
ment  groups was considered via a test for heterogeneity
but was not deemed necessary in the ﬁnal analysis.
3. Results and discussion
There  were no adverse events within the 8 h post treat-
ment period, and no abnormal respiratory signs were
detected in any of the dogs treated with spinosad/MO.
Auscultation revealed minor intensity respiratory sounds
in  two dogs in the placebo group, one on Days 7 and 12,
and  one on Day 12. No other physical abnormalities were
observed in any dog during the study period, and a pre-
necropsy physical examination of each dog did not detect
any  clinical abnormalities.
Faecal  samples taken each day in the treatment phase,
starting 40 post inoculation until a dog was positive,
revealed that all dogs in group A (placebo) were shedding
larvae between 47 and 54 dpi, with larval counts ranging
from 2 to 46 per 10 g of faeces. The objective of the faecal
counts was to demonstrate patency, and it is likely that sub-
sequent  samples would have yielded increasingly higher
counts. At no point during the study were larvae detected
in  the faeces of dogs in the treated group B.
Necropsy examinations for the presence of A. vasorum
demonstrated adequate infection in all eight control
(placebo-treated) dogs, with adult worm counts ranging
from  22 to 98, and the GM worm count was 55.2. In the
spinosad/MO group, no worms were found in 5 dogs;
counts in the 3 dogs in which A. vasorum were detected
were 1, 2 and 8. The GM worm count in the spinosad/MO
group was 0.7, which, relative to the placebo group,
met  the required reduction in counts to demonstrate
effectiveness. The objective of the study was met  as the
results demonstrated a signiﬁcant difference between
the control and treated groups (p < 0.0001). The GM
efﬁcacy of spinosad/MO in the treated group versus the
placebo-treated group was 98.8%.
Gross necropsy ﬁndings were similar to the ﬁndings of
Schnyder et al. (2009). Macroscopic changes in the lungs
varied considerably between the groups but were consis-
tent  within each group. Generally, the lungs appeared pale
and  anaemic, likely a result of the necropsy procedure of
ﬂushing  the blood out of the lungs. In the lungs of dogs
in  the spinosad/MO group, there were faintly visible lung
changes observed as a pattern of disseminated pale pink
coalescing, slightly consolidated, raised foci. In some cases
these  foci were associated with darker red haemorrhagic
areas, but usually had a yellow tinge from degrading haem-
orrhages (Fig. 1). In contrast, the lungs of all the dogs in
the  control group (Fig. 2) were severely affected with large
conﬂuent areas that were ﬁrm, raised, and discoloured
from pale beige to yellow to dark red. Fresh haemorrhages,
alternating with pale non-aerated areas conﬁrmed severe
damage to the lungs, consistent with those that have beenulated with 250 third stage larvae of Angiostrongylus vasorum. This dog
showed respiratory signs on Days 7 and 12 after treatment and had 93
worms  at necropsy performed 26 days after placebo administration.
described as a consequence of an established lungworm
infection (Schnyder et al., 2009).
4. Conclusion
Traditionally, treatment of A. vasorum infections has
been  complicated by the need for repeat-treatment regi-
mens,  and only a single study has demonstrated the
potential for prevention of the establishment of adult infec-
tions  (Schnyder et al., 2009). In that study, the full topical
dose of imidacloprid/moxidectin administered under lab-
oratory  conditions was found to be completely effective,
indicating that monthly applications according to label rec-
ommendations should offer a reliable means of preventing
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he effects of A. vasorum infection. Because of reported con-
erns  that some owners or veterinarians have expressed
bout topically applied products, including the effects of
nclement weather and bathing, and the difﬁculties some
wners  appear to have in applying a full topical dose
irectly to a dogs skin, it is important to have alternative
reatments that can be administered orally (Snyder et al.,
007;  Dryden et al., 2013).
The  results of this study indicate that the combination
ablet of spinosad/MO provides such an oral alternative.
 single treatment with the ﬂavoured combination tablet
ontaining spinosad and MO,  at the lower end of the
xpected label dose range for this formulation, was  found to
e  >98% effective in preventing the development of infec-
ions  with adult A. vasorum in study dogs. Additionally, a
ingle  treatment with the combination product substan-
ially reduced the subsequent pulmonary damage caused
y  A. vasorum infections, relative to the pathology observed
n  control dogs. Such pathology is most likely due to the
roduction of ﬁrst stage larvae once adult A. vasorum have
ecome  established.
As  such, regular monthly treatment with the
pinosad/MO chewable tablets is expected to prevent
ogs from developing clinical or subclinical disease
ssociated with A. vasorum infection. By preventing devel-
pment  of infection to the adult stage, this treatment has
he  potential to interrupt the parasite life cycle and to help
imit  the environmental accumulation of infective larval
tages  and thus snails will not become infected.
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